Cargando…

Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies

The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western cou...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amelio, Raffaele, Asero, Riccardo, Cassatella, Marco Antonio, Laganà, Bruno, Lunardi, Claudio, Migliorini, Paola, Nisini, Roberto, Parronchi, Paola, Quinti, Isabella, Racanelli, Vito, Senna, Gianenrico, Vacca, Angelo, Maggi, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465958/
https://www.ncbi.nlm.nih.gov/pubmed/34572349
http://dx.doi.org/10.3390/biomedicines9091163
_version_ 1784573009156112384
author D’Amelio, Raffaele
Asero, Riccardo
Cassatella, Marco Antonio
Laganà, Bruno
Lunardi, Claudio
Migliorini, Paola
Nisini, Roberto
Parronchi, Paola
Quinti, Isabella
Racanelli, Vito
Senna, Gianenrico
Vacca, Angelo
Maggi, Enrico
author_facet D’Amelio, Raffaele
Asero, Riccardo
Cassatella, Marco Antonio
Laganà, Bruno
Lunardi, Claudio
Migliorini, Paola
Nisini, Roberto
Parronchi, Paola
Quinti, Isabella
Racanelli, Vito
Senna, Gianenrico
Vacca, Angelo
Maggi, Enrico
author_sort D’Amelio, Raffaele
collection PubMed
description The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force. Patients with AIADs, PIDs, and SIDs: (1) Do not present contraindications to COVID-19 vaccines if a mRNA vaccine is used and administered in a stabilized disease phase without active infection. (2) Should usually not discontinue immunosuppressive therapy, which may be modulated depending on the patient’s clinical condition. (3) When eligible, should have a priority access to vaccination. In fact, immunizing these patients may have relevant social/health consequences, since these patients, if infected, may develop chronic infection, which prolongs viral spread and facilitates the emergence of viral variants.
format Online
Article
Text
id pubmed-8465958
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84659582021-09-27 Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies D’Amelio, Raffaele Asero, Riccardo Cassatella, Marco Antonio Laganà, Bruno Lunardi, Claudio Migliorini, Paola Nisini, Roberto Parronchi, Paola Quinti, Isabella Racanelli, Vito Senna, Gianenrico Vacca, Angelo Maggi, Enrico Biomedicines Review The Coronavirus disease 2019 (COVID-19) pandemic has represented an unprecedented challenge for humankind from health, economic, and social viewpoints. In February 2020, Italy was the first western country to be deeply hit by the pandemic and suffered the highest case/fatality rate among western countries. Brand new anti-COVID-19 vaccines have been developed and made available in <1-year from the viral sequence publication. Patients with compromised immune systems, such as autoimmune-autoinflammatory disorders (AIAIDs), primary (PIDs) and secondary (SIDs) immunodeficiencies, have received careful attention for a long time regarding their capacity to safely respond to traditional vaccines. The Italian Immunological Societies, therefore, have promptly faced the issues of safety, immunogenicity, and efficacy/effectiveness of the innovative COVID-19 vaccines, as well as priority to vaccine access, in patients with AIADs, PIDs, and SIDs, by organizing an ad-hoc Task Force. Patients with AIADs, PIDs, and SIDs: (1) Do not present contraindications to COVID-19 vaccines if a mRNA vaccine is used and administered in a stabilized disease phase without active infection. (2) Should usually not discontinue immunosuppressive therapy, which may be modulated depending on the patient’s clinical condition. (3) When eligible, should have a priority access to vaccination. In fact, immunizing these patients may have relevant social/health consequences, since these patients, if infected, may develop chronic infection, which prolongs viral spread and facilitates the emergence of viral variants. MDPI 2021-09-04 /pmc/articles/PMC8465958/ /pubmed/34572349 http://dx.doi.org/10.3390/biomedicines9091163 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
D’Amelio, Raffaele
Asero, Riccardo
Cassatella, Marco Antonio
Laganà, Bruno
Lunardi, Claudio
Migliorini, Paola
Nisini, Roberto
Parronchi, Paola
Quinti, Isabella
Racanelli, Vito
Senna, Gianenrico
Vacca, Angelo
Maggi, Enrico
Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title_full Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title_fullStr Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title_full_unstemmed Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title_short Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies
title_sort anti-covid-19 vaccination in patients with autoimmune-autoinflammatory disorders and primary/secondary immunodeficiencies: the position of the task force on behalf of the italian immunological societies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465958/
https://www.ncbi.nlm.nih.gov/pubmed/34572349
http://dx.doi.org/10.3390/biomedicines9091163
work_keys_str_mv AT damelioraffaele anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT aseroriccardo anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT cassatellamarcoantonio anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT laganabruno anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT lunardiclaudio anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT migliorinipaola anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT nisiniroberto anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT parronchipaola anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT quintiisabella anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT racanellivito anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT sennagianenrico anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT vaccaangelo anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties
AT maggienrico anticovid19vaccinationinpatientswithautoimmuneautoinflammatorydisordersandprimarysecondaryimmunodeficienciesthepositionofthetaskforceonbehalfoftheitalianimmunologicalsocieties